Shanxi Zhendong PharmaceuticalLtd マネジメント

マネジメント基準チェック /24

We currently do not have sufficient information about the CEO.

主要情報

Lianmin Yang

最高経営責任者

CN¥678.5k

報酬総額

CEO給与比率	n/a
CEO在任期間	2.9yrs
CEOの所有権	n/a
経営陣の平均在職期間	2.9yrs
取締役会の平均在任期間	2.6yrs

経営陣の近況

Recent updates

Improved Revenues Required Before Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Stock's 39% Jump Looks Justified

Oct 22

We Think Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Can Afford To Drive Business Growth

Sep 30

Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Low P/S No Reason For Excitement

Aug 08

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Mar 07

CEO（最高経営責任者

Lianmin Yang (61 yo)

2.9yrs

在職期間

CN¥678,500

報酬

Mr. Lianmin Yang is President of Shanxi Zhendong Pharmaceutical Co.,Ltd from December 02, 2021 and had been its Deputy General Manager since April 24, 2021 and serves as its Director. He has M.B.A. from Ch...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Lianmin Yang	President & Director	2.9yrs	CN¥678.50k	データなし
Changlu Liu	Head of Accounting & CFO	6.1yrs	CN¥375.40k	データなし
Zheyu Wang	VP & Secretary of the Board of Director	1.5yrs	CN¥521.50k	データなし
Xufeng Wang	Executive GM & Director	no data	データなし	データなし

2.9yrs

平均在職期間

40yo

平均年齢

経験豊富な経営陣: 300158's management team is considered experienced (2.9 years average tenure).

取締役

名称	ポジション	在職期間	報酬	所有権
Lianmin Yang	President & Director	no data	CN¥678.50k	データなし
Xufeng Wang	Executive GM & Director	1.6yrs	データなし	データなし
Zhixiang Jin	Supervisor	12.9yrs	データなし	0.077% CN¥ 3.8m
Ren Hu Li	Chairman of the Supervisory Board	15.9yrs	データなし	0.084% CN¥ 4.1m
Zhimin Wang	Director	15.9yrs	CN¥83.30k	データなし
Jing Li	Director	6.3yrs	CN¥694.70k	データなし
Kun Li	Director	2.6yrs	CN¥688.30k	データなし
Lina Jin	Independent Director	less than a year	データなし	データなし
Wanliang Lv	Independent Director	less than a year	データなし	データなし
Xuemei Qin	Independent Director	9.4yrs	データなし	データなし
Jiawen Ai	Non-Independent Director	less than a year	データなし	データなし
Zhenhong Lei	Supervisor	less than a year	データなし	データなし

2.6yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: 300158's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Shanxi Zhendong PharmaceuticalLtd マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board and Non-Employee Supervisor Elections

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

No independent directors

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: CN¥0.009 (vs CN¥0.018 loss in 3Q 2023)

Improved Revenues Required Before Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Stock's 39% Jump Looks Justified

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 24, 2024

We Think Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Can Afford To Drive Business Growth

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board and Non-Employee Supervisor Elections

Second quarter 2024 earnings released: EPS: CN¥0.007 (vs CN¥0.014 in 2Q 2023)

Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Low P/S No Reason For Excitement

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 27, 2024

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.043 loss per share (vs CN¥0.05 loss in FY 2022)

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Now 20% undervalued

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0 in 3Q 2022)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: CN¥0.014 (vs CN¥0.015 in 2Q 2022)

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥2.55 profit in FY 2021)

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.015 (vs CN¥0.12 in 2Q 2021)

Upcoming dividend of CN¥2.70 per share

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 09 May 2022

No independent directors

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves 2021 Profit Distribution Plan

Investor sentiment deteriorated over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2022

Shanxi Zhendong Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.087 in 3Q 2020)

Investor sentiment deteriorated over the past week

FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. entered into an agreement to acquire Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) for CNY 5.8 billion.

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.055 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Final Profit for 2020

Shanxi Zhendong Pharmaceutical Co.,Ltd Announces Final Profit Distribution Proposal for 2020

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.14 in FY 2019)

New 90-day low: CN¥4.39

Investor sentiment deteriorated over the past week

New 90-day low: CN¥5.46

New 90-day low: CN¥5.73

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day high - CN¥6.39

New 90-day high - CN¥6.05

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24